XSHG
600557
Market cap1.03bUSD
Oct 09, Last price
12.40CNY
1D
1.47%
1Q
0.00%
Jan 2017
-26.76%
IPO
471.43%
Name
Jiangsu Kanion Pharmaceutical Co Ltd
Chart & performance
P/E
23.10
P/S
2.15
EPS
0.54
Div yield, %
3.04%
Shrs. gr., 5y
-1.07%
Rev. gr., 5y
1.50%
Revenues
3.27b
-16.20%
Net income
304m
-22.44%
CFO
621m
-11.62%
Dividend
May 31, 20240.37203 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Kanion Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise focused on the research, development, production, and distribution of traditional Chinese medicines. The company's diverse product range targets several therapeutic areas, such as women's health, bone and joint conditions, antiviral treatments, and cardiovascular and cerebrovascular ailments. Founded in 1975, its primary operations are based in Lianyungang, China.
Key people
Wei Xiao
Chairman of the Board · since 2023
Qing Li
Chief Financial Officer · since 2025
Yongchun Yang
General Manager, Director · since 2021
Quan Liu
Deputy General Manager · since 2019
Yu Pan
Deputy General Manager · since 2022
Chuanlei Wang
Deputy General Manager · since 2022
Tuanjie Wang
Deputy General Manager · since 2024
Peng Pan
Secretary of the Board · since 2024
Xuebin Chen
Director · since 2023
Haixin Gao
Director · since 2024
Ya Ling
Director · since 2025
Lihao Xiao
Director · since 2025
Kaixian Chen
Independent Director · since 2019
Jin'ao Duan
Independent Director · since 2023
Min Xu
Independent Director · since 2021
Independent Director · since 2025
Headquarters & legal address
市连云港经济技术开发区江宁工业城
连云港市, JS 100000
CN
连云港市, JS 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||